Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Anlotinib in ES-SCLC After Anti-PD-1/L1 Therapy Failure
NCT07022301Phase 2Not yet recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, anlotinib in small cell lung cancer (SCLC), sponsored by Yejishan Hospital of Wannan Medical College. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07022301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022301.